Company intelligence / Profile preview

Aridis Pharmaceuticals, Inc.

San Jose, California, United Statesaridispharma.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Aridis has multiple clinical-stage programs with AR-301 and AR-320 in Phase 3 trials for VAP, and AR-501 having completed Phase 2a trials for cystic fibrosis. The company recently executed an Asset Acquisition Terms Agreement for AR-501 worth $6,500,000 and is working with an investment firm to fund the completion of AR-301's second Phase 3 study.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Monoclonal antibodies (mAbs)Small moleculesAnti-infectivesImmunotherapies
Industry: Biotech

Drug pipeline

12 assets

Suvratoxumab

11 more assets in the full pipeline.

Request access →

Partnerships

National Institute of Allergy and Infectious DiseasesHarvard UniversityUndisclosed pharmaceutical company (AR-501 acquisition)

Beyond the preview

Go deeper on Aridis Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aridis Pharmaceuticals, Inc..

Explore the full profile